Title:
PHARMACEUTICAL COMPOSITION FOR TREATMENT OR ALLEVIATION OF PULMONARY FIBROSIS AND ASTHMA
Document Type and Number:
WIPO Patent Application WO/2018/105943
Kind Code:
A1
Abstract:
The present invention relates to a pharmaceutical composition for treatment of pulmonary fibrosis or neutrophilic asthma or alleviation of symptoms thereof, comprising or using, as active ingredients, laquinimod, paquinimod, and tasquinimod or pharmaceutically acceptable salts thereof, and preferably paquinimod or a pharmaceutically acceptable salt thereof for use in treatment or alleviation of pulmonary fibrosis, and tasquinimod or a pharmaceutically acceptable salt thereof for use in treatment or alleviation of neutrophilic asthma. That is, the present invention relates to a new medicinal use of laquinimod, paquinimod, tasquinimod or pharmaceutically acceptable salts thereof.
Inventors:
PARK CHOON SIK (KR)
Application Number:
PCT/KR2017/013799
Publication Date:
June 14, 2018
Filing Date:
November 29, 2017
Export Citation:
Assignee:
UNIV SOONCHUNHYANG IND ACAD COOP FOUND (KR)
International Classes:
A61K31/4704; A61K31/404; A61K31/4412; A61K45/06
Foreign References:
| KR20010053115A | 2001-06-25 | |||
| JP2013177351A | 2013-09-09 | |||
| KR20140035493A | 2014-03-21 | |||
| KR20010043066A | 2001-05-25 |
Other References:
STENSTROM, M. ET AL.: "Paquinimod Reduces Skin Fibrosis in Tight Skin 1 Mice, an Experimental Model of Systemic Sclerosis", JOURNAL OF DERMATOLOGICAL SCIENCE, vol. 83, no. 1, July 2016 (2016-07-01), pages 52 - 59, XP029569709
XAUBET, A. ET AL.: "Pirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis", EXPERT OPINION ON PHARMACOTHERAPY, vol. 15, no. 2, 2014, pages 275 - 281, XP055515933
XAUBET, A. ET AL.: "Pirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis", EXPERT OPINION ON PHARMACOTHERAPY, vol. 15, no. 2, 2014, pages 275 - 281, XP055515933
Attorney, Agent or Firm:
PHIL & ONZI INT'L PATENT & LAW FIRM (KR)
Download PDF: